Non-Coronary Vascular Stents: Renal artery

January 16th, 2018 - Find-A-Code
Categories:   CPT® Coding   Diagnosis Coding   Cardiology|Vascular  
0 Votes - Sign in to vote or comment.

The following information is according to Novitas Solutions L35084.

Renal artery: Stenting may be indicated for renal artery stenosis causing renovascular hypertension (see below) or renal insufficiency as well as post-transplant renal artery stenosis, arterial aneurysm or dissection. Renal artery angioplasty with or without stenting is covered for renal artery stenosis manifested by at least one of the following conditions:

  • Recurrent (“flash”) pulmonary edema without cardiac or other obvious etiology and with renal artery stenosis of greater than or equal to 60 percent of the vessel diameter.
  • Rapidly progressive renal insufficiency or acute renal failure in patients at risk for renal artery stenosis when another cause for renal deterioration has been sought and is not present, and with renal artery stenosis of greater than or equal to 75 percent of the vessel diameter and with one of the following in addition to progressive renal insufficiency:
    • Coexisting diffuse atherosclerotic vascular disease.
    • Acute renal failure precipitated by antihypertensive therapy, particularly angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.
  • Renal artery dissection.
  • Renal artery aneurysm.
  • Renal artery stenosis greater than or equal to 50 percent in a transplanted kidney. 

Renovascular hypertension (all criteria must be met):

  • Hypertension is not controlled (lowest blood pressure recorded by a physician of 160 mm Hg systolic or 90 mm Hg diastolic or 160 mm Hg in patients with isolated systolic hypertension despite documented adherence to treatment with maximum accepted doses of three or more antihypertensive medications.
  • Renal artery stenosis demonstrated by renal arteriography with luminal cross-sectional area reduction of 75 percent or vessel diameter narrowing greater than 50 percent. Stenting of renal artery stenosis of less than 75 percent reduction of luminal cross-sectional area/50 percent reduction of vessel diameter may be indicated when renal vein renin studies clearly indicate renal artery stenosis to be the cause of the elevated blood pressure.
Medicare is establishing the following limited coverage for CPT/HCPCS codes 37236 and 37237:

CPT codes:

ICD-10-CM codes:
  • I70.1* - Atherosclerosis of renal artery
  • I72.2 - Aneurysm of renal artery
  • I75.81 - Atheroembolism of kidney
  • I77.3* - Arterial fibromuscular dysplasia
  • I77.73 - Dissection of renal artery
  • Q27.1 - Congenital renal artery stenosis
  • Q27.2 - Other congenital malformations of renal artery
  • Q27.34 - Arteriovenous malformation of renal vessel
  • Kidney transplant
*Note: I70.1 and I77.3 require an additional code for coverage of renal artery stenting. These codes fulfill medical necessity:
  • Hypertensive chronic kidney disease
    • I12.0 - with stage 5 chronic kidney disease or end stage renal disease
    • I12.9 - with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease
  • Hypertensive heart and chronic kidney disease
    • I13.0 - with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease
    • I13.10 - without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease
    • I13.11 - without heart failure, with stage 5 chronic kidney disease, or end stage renal disease
    • I13.2 - with heart failure and with stage 5 chronic kidney disease, or end stage renal disease
  • I15.0 - Renovascular hypertension
  • I15.1 - Hypertension secondary to other renal disorders
  • J81.0 - Acute pulmonary edema
  • N17.8 - Other acute kidney failure
  • N17.9 - Acute kidney failure, unspecified
  • N26.2 - Page kidney


Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.

Latest articles:  (any category)

Where is the CCI Edit with Modifier 25 on E/M?
May 20th, 2020 - Christine Woolstenhulme, QCC, CMCS, CPC, CMRS
If you are not seeing a CCI edit when reporting an E/M code with a certain procedure, it may be that there is no edit. CMS does not have a CCI edit for every CPT code, however, there are still general coding rules that must be followed.  The use of Modifier 25 is one example ...
Packaging and Units for Billing Drugs
May 18th, 2020 - Christine Woolstenhulme, QCC, CMCS, CPC, CMRS
To determine the dosage, size, doses per package and how many billing units are in each package, refer to the NDC number. Take a look at the following J1071 - Injection, testosterone cypionate, 1mg For example; using NCD # 0009-0085-10 there are 10 doses of 100 mL (100 mg/mL = 1 mL and there are ...
Getting Your Practice Back on Track
May 12th, 2020 - Wyn Staheli, Director of Research
As we begin returning back to work, we will all face a new normal. The COVID-19 pandemic has changed the face of business. While it has certainly been a challenge to keep up with the ever-changing regulations (that’s likely to continue for a little longer), exciting new opportunities have also been created, such as the expansion of telemedicine. There’s also the maze of government funding that needs to be navigated and an increased awareness of OSHA standards to implement.
ICD-10-CM - Supplement information for E-Cigarette/Vaping Reporting
May 5th, 2020 - Christine Woolstenhulme, QCC, CMCS, CPC, CMRS
The CDC has released additional information and coding guidance for reporting encounters related to the 2019 health care encounters and deaths related to e-cigarette, or vaping, product use associated lung injury (EVALI).  The update offers coding scenarios for general guidance, poisoning and toxicity, substance abuse and signs and symptoms.  ICD-10-CM Official Coding Guidelines - ...
Additional Telehealth Changes Announced by CMS
May 4th, 2020 - Wyn Staheli, Director of Research
On April 30, 2020, CMS announced additional sweeping changes to meet the challenges of providing adequate healthcare during this pandemic. These changes expand the March 31st changes. The article covers some of the key changes. See the official announcement in the references below.
Effective Risk Adjustment Requires Accurate Calculations
April 27th, 2020 - Wyn Staheli, Director of Research
Risk adjustment is simply a way of making sure that there are sufficient funds to adequately take care of the healthcare needs of a certain population. It’s a predictive modeling methodology based on the diagnoses of the individuals in that population. As payers move to value based models, they heavily rely on risk adjustment to ensure proper funding.
COVID-19 Clinical Trial Participation Helps Providers Earn MIPS Credit
April 22nd, 2020 - Wyn Staheli, Director of Research
All healthcare providers who are currently participating in the MIPS portion of Medicare’s Quality Payment Program may want to participate in the new COVID-19 Clinical Trials improvement activity. Read more about it here.

Home About Contact Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2020 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association